Results 101 to 110 of about 469,352 (221)

Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013. [PDF]

, 2015
In 2011, vaccination with a serogroup A meningococcal polysaccharide conjugate vaccine was implemented in 3 of 23 regions in Chad. Cases of meningitis declined dramatically in vaccinated areas, but an epidemic continued in the rest of Chad.
Greenwood, Brian M, Ngadoua, C, Kadidja Gamougam, Dominique A. Caugant, Trotter, Caroline L, Toralta, J, Greenwood, B M, Ngadoua, Cyriaque, Fermon, Florence, Manigart, Olivier, Daugla, D M, Olivier Manigart, Daugla, Doumagoum M, Florence Fermon, Page, A-L, Caugant, D A, Djingarey, M H, Doumagoum M. Daugla, Fermon, F, James M. Stuart, Page, Anne-Laure, Trotter, C L, Caugant, Dominique A, Djingarey, Mamoudou H, Anne-Laure Page, Mamoudou Djingarey, Gamougam, Kadidja, Cyriaque Ngadoua, Toralta, Jacques, Stuart, J M, Stuart, James M, Gamougam, K, Manigart, O, Caroline L. Trotter, Jacques Toralta, Brian M. Greenwood   +35 more
core   +1 more source

Death or survival from invasive pneumococcal disease in Scotland: associations with serogroups and multilocus sequence types [PDF]

, 2011
We describe associations between death from invasive pneumococcal disease (IPD) and particular serogroups and sequence types (STs) determined by multilocus sequence typing (MLST) using data from Scotland.
Mitchell, Tim J, Mitchell, T.J., Jefferies, J.M.C., Greenhalgh, D., Stuart C. Clarke, David Greenhalgh, Lamb, Karen Elaine, McMenamin, Jim, Robertson, C., Inverarity, D., Greenhalgh, D, Diggle, M, Jim McMenamin, Mathew Diggle, Lamb, K, Clarke, S., Edwards, Giles F S, Jefferies, JMC, Mitchell, T., Lamb, K., Johanna M. C. Jefferies, Clarke, SC, Tim J. Mitchell, Clarke, Stuart C, Clarke, S.C., Edwards, G.F.S., Mitchell, Tim J., Inverarity, D, Diggle, Mathew, Smith, A, Inverarity, Donald, McMenamin, J., Smith, Andrew, Mitchell, TJ, McMenamin, J, Lamb, Karen, Robertson, C, Diggle, M., Greenhalgh, David, Andrew Smith, Donald Inverarity, Edwards, G., Smith, A., Clarke, Stuart C., Jefferies, Johanna M C, Jerreries, J., Chris Robertson, Edwards, Giles F.S., Karen Lamb, Jefferies, Johanna M.C., Robertson, Chris, Giles F. S. Edwards, Edwards, GFS   +52 more
core   +1 more source

In-vitro and in-vivo expression analysis of pneumococcal vaccine candidates: pilus-1 components [PDF]

, 2011
Streptococcus pneumoniae (S. pneumoniae) is a Gram-positive commensal of the nasopharyngeal tract of both children and healthy adults. However, S. pneumoniae is also a leading cause of morbidity and mortality worldwide, being responsible for non-invasive
De Angelis, Gabriella
core   +1 more source

The New Era of Pneumococcal Vaccination in Adults: What Is Next?

Vaccines
Streptococcus pneumoniae remains the leading cause of community-acquired pneumonia in adults and bacterial meningitis in children worldwide. In addition to pneumonia, invasive pneumococcal diseases (IPDs), such as bacteremia and meningitis, pose a ...
Lale Ozisik
doaj   +1 more source

Pneumococcal conjugate vaccines—a European perspective

International Journal of Medical Microbiology, 2004
Streptococcus pneumoniae is a leading cause of bacterial pneumonia, meningitis, and acute otitis media in children and adults worldwide. In the age group of < 2 years the incidence of invasive pneumococcal disease ranges from approximately 14 cases per 100,000 in Germany and the Netherlands and more than 90 per 100,000 children in Spain.
openaire   +2 more sources

Recent Advances in Pneumococcal Conjugate Vaccines: A 13-Valent Pneumococcal Conjugate Vaccine

Journal of Pediatric Infection, 2011
Streptococcus pneumoniae (pneumococcus) is an important cause of serious infectious diseases, leading to death among children all over the world. The 7-valent pneumococcal conjugate vaccine (PCV7), which was introduced in 2000 to prevent pneumococcal infections, was included in the Childhood National Immunization Program of Turkey in November 2008 and ...
openaire   +2 more sources

Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis

Health Technology Assessment
Background Vaccination of infants with pneumococcal conjugate vaccines is recommended by the World Health Organization. Evidence is mixed regarding the differences in immunogenicity and efficacy of the different pneumococcal vaccines.
Shuo Feng, Julie McLellan, Nicola Pidduck, Nia Roberts, Julian PT Higgins, Yoon Choi, Alane Izu, Mark Jit, Shabir A Madhi, Kim Mulholland, Andrew J Pollard, Simon Procter, Beth Temple, Merryn Voysey   +13 more
doaj   +1 more source

Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: A longitudinal household study [PDF]

, 2005
Background. Natural immunity to Streptococcus pneumoniae is thought to be induced by exposure to S. pneumoniae or cross-reactive antigens. No longitudinal studies of carriage of and immune responses to S.
Hussain, M, Virta, C, Soininen, A, Kayhty, H, Miller, E, Ashton, L, Edmunds, J, Gay, N, Goldblatt, D, Andrews, N, George, R, Pebody, R, Melegaro, A   +12 more
core  

Vaccine [PDF]

We applied the indirect cohort method to estimate effectiveness of 10-valent pneumococcal conjugate vaccine (PCV10) among young children in Brazil. Cases of invasive pneumococcal disease (IPD), i.e., Streptococcus pneumoniae, detected in normally sterile

core  

Neutrophils induce effective antibody responses to the pneumococcal conjugate vaccine by inhibiting T regulatory cells. [PDF]

J Leukoc Biol
Tchalla EYI, Betadpur A, Khalil AY, Lopez E, Bhalla M, Chang M, Wohlfert EA, Bou Ghanem EN.   +7 more
europepmc   +1 more source